3,5-Diiodothyropropionic acid (Standard)

3,5-Diiodothyropropionic acid (Standard) is the analytical standard of 3,5-Diiodothyropropionic acid. This product is intended for research and analytical applications. 3,5-Diiodothyropropionic acid is a thyroid hormone analog, induces α-myosin heavy chain mRNA expression, binds to thyroid hormone receptor (TR), with Ka of 2.40 and 4.06 M-1 for TRα1 and TRβ1, respectively. 3,5-Diiodothyropropionic acid promotes angiogenesis in 3-D human dermal microvascular endothelial cell sprouting assay. 3,5-Diiodothyropropionic acid prevents myocardial arteriolar loss in thyroidectomized rats and enhances cardiac energy-generating capacity in postinfarction heart failure rats. 3,5-Diiodothyropropionic can be used in studies related to angiogenesis and heart failure[1][2][3][4].

Product Specifications

CAS Number

[1158-10-7]

UNSPSC

12352100

Target

Reference Standards; Thyroid Hormone Receptor

Related Pathways

Others; Vitamin D Related/Nuclear Receptor

Field of Research

Cardiovascular Disease; Endocrinology

Smiles

O=C(O)CCC1=CC(I)=C(OC2=CC=C(O)C=C2)C(I)=C1

Molecular Formula

C15H12I2O4

Molecular Weight

510.06

References & Citations

[1]Pennock GD, et al. Cardiac effects of 3,5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J Pharmacol Exp Ther. 1992 Oct;263 (1) :163-9. |[2]Liu Y, et al. Thyroid hormone analog 3,5-diiodothyropropionic acid promotes healthy vasculature in the adult myocardium independent of thyroid effects on cardiac function. Am J Physiol Heart Circ Physiol. 2009 May;296 (5) :H1551-7. |[3]Maitra N, et al. Regulation of gene expression in rats with heart failure treated with the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) and the combination of DITPA and captopril. J Cardiovasc Pharmacol. 2007 Nov;50 (5) :526-34. |[4]Mousa SA, et al. Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology. 2006 Apr;147 (4) :1602-7.